and resistance -T790Msubstitutions and the different generations of EGFR inhibitors (EGFRi) developed to achieve selective bioactivity profiles (as a reference commonly used in drug discovery we will consider a potency difference over 30-fold against specific variants of interest, which translates to a pChEMBL value difference over 1.5). The bioactivity analysis set for EGFR was generated from a common subset with compounds tested on at least three EGFR variants and variants covering at least 10% of the compounds. The analysis subset contained 22 compounds tested on nine out of the 14 annotated EGFR variants with clear differences in bioactivity (Figure , see Supplementary Figure for compound ID mapping).